Search results for "pharmacophore model"

showing 9 items of 19 documents

Reliability of Virtual Screening Methods in Prediction of PDE4Binhibitor Activity

2015

Identification of active ligands using computational methods is a challenging task. For example, molecular docking, pharmacophore modeling, and three dimensional quantitative structure-activity relationship models (3D-QSAR) are widely used methods to identify novel small molecules. However, all these methods have, in addition to advantages, also significant pitfalls. The aim of this study was to compare some commonly used computational methods to estimate their ability to separate highly active PDE4B-inhibitors from less active and inactive ones. Here, 152 molecules with pIC 50 -range of 3.4-10.5, originating from six original studies were used. High correlation coefficients by using dockin…

Computer scienceQuantitative Structure-Activity RelationshipMultiple methodsLigandsComputers MolecularDrug DiscoveryProtein Interaction MappingHumansSimulationPharmacological Phenomenathree-dimensional quantitative structure-activity relationshipVirtual screeningbusiness.industryta1182Pattern recognitionmolecular dockingmolecular mechanics-generalized born-surface areavirtual screeningCyclic Nucleotide Phosphodiesterases Type 4Molecular Docking SimulationDocking (molecular)pharmacophore modelingArtificial intelligencePhosphodiesterase 4 InhibitorsPharmacophorebusinessphosphodiesteraseCurrent Drug Discovery Technologies
researchProduct

Computational methodologies in the discovery of inhibitors of HIV-1

2009

HIV-1 reverse trascriptaseHIV-1 proteasedockingpharmacophore modelingmultivariate analysiSettore CHIM/08 - Chimica FarmaceuticaHIV-1 inhibitor
researchProduct

Pharmacophore modelling as useful tool in the lead compounds identification and optimization

2012

The goal of computer-aided molecular design methods in modern medicinal chemistry is to reduce the overall cost and time associated to the discovery and development of a new drug by identifying the most promising candidates to focus the experimental efforts on. Very often, many drug discovery projects have reached already a well-advanced stage before detailed structural data on the protein target have become available. A possible consequence is that often, medicinal chemists develop novel compounds for a target using preliminary structure–activity information, together with the theoretical models of interactions. Only responses that are consistent with the working hypothesis contribute to a…

PHARMACOPHORE MODELLING LEAD IDENTIFICATION AND OPTIMIZATIONSettore CHIM/08 - Chimica Farmaceutica
researchProduct

3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.

2010

Bcl-2 proteins family members play several roles in tumoral proliferation: they inhibit proapoptotic activity during oncogenesis, support tumor cells survival, induce chemoresistance. The discovery of new small inhibitors of Bcl-xl represents a new frontier for cancer treatment. In this study, a 3D-QSAR pharmacophore model was developed, based on 42 biarylacylsulfonamides, and used to understand the structural factors affecting the inhibitory potency of these derivatives. Aromatic, negative charge, and hydrogen bond acceptor effects contribute to the inhibitory activity. The model was then employed as 3D search query to screen ZINC drug-like database in order to select new scaffolds. Finall…

PharmacologyModels MolecularVirtual screeningQuantitative structure–activity relationshipTertiary amineMolecular modelChemistryIn silicoOrganic ChemistryMolecular Conformationbcl-X ProteinQuantitative Structure-Activity RelationshipGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaBiochemistryIn vivoDocking (molecular)Drug Discovery3D-QSAR Pharmacophore Modeling In Silico Screening Bcl-xl InhibitorsPharmacophoreEuropean journal of medicinal chemistry
researchProduct

Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors

2019

[EN] The development and advancement of prostate cancer (PCa) into stage 4, where it metastasize, is a major problem mostly in elder males. The growth of PCa cells is stirred up by androgens and androgen receptor (AR). Therefore, therapeutic strategies such as blocking androgens synthesis and inhibiting AR binding have been explored in recent years. However, recently approved drugs (or in clinical phase) failed in improving the expected survival rates for this metastatic-castration resistant prostate cancer (mCRPC) patients. The selective CYP17A1 inhibition of 17,20-lyase route has emerged as a novel strategy. Such inhibition blocks the production of androgens everywhere they are found in t…

Quantitative structure–activity relationshipStereochemistry01 natural sciencesBiochemistryStructure-Activity Relationship3D-QSAR pharmacophore modelDrug DiscoveryCytochrome P-450 Enzyme InhibitorsHumansStructure–activity relationshipCYP17A1 InhibitorMolecular BiologyDensity Functional TheoryVirtual screeningDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryProspective computational designSteroid 17-alpha-Hydroxylasecomputer.file_format1720-lyase selective inhibitionProtein Data BankLyase0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)CYP17A1 inhibitorsMetastatic-castration resistant prostate cancerPharmacophorecomputer
researchProduct

In Silico Design, Synthesis and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity

2022

Telomerase, a reverse transcriptase enzyme involved in DNA synthesis, has a tangible role in tumor progression. Several studies have evidenced telomerase as a promising target for developing cancer therapeutics. The main reason is due to the overexpression of telomerase in cancer cells (85–90%) compared with normal cells where it is almost unexpressed. In this paper, we used a structure-based approach to design potential inhibitors of the telomerase active site. The MYSHAPE (Molecular dYnamics SHared PharmacophorE) approach and docking were used to screen an in-house library of 126 arylsulfonamide derivatives. Promising compounds were synthesized using classical and green methods. Com…

SulfonamidesRPharmaceutical ScienceAnticancer compounds; Arylsulfonamide; Docking; Molecular dynamics; Pharmacophore modeling; Structure-based drug design; Sulfonamides; Telomerase inhibitorsMolecular dynamicsSettore CHIM/08 - Chimica FarmaceuticaArticleDockingRS1-441Anticancer compoundsTelomerase inhibitorsPharmacy and materia medicaDrug DiscoveryArylsulfonamideMedicineMolecular Medicinesulfonamides; arylsulfonamide; anticancer compounds; telomerase inhibitors; structure-based drug design; pharmacophore modeling; docking; molecular dynamicsStructure-based drug designPharmacophore modeling
researchProduct

TOWARD ENRICHED VHTS FOR CDK2 INHIBITORS: MOLECULAR DYNAMICS, PHARMACOPHORE MODELLING, AND DOCKING

2019

Cyclin-Dependent Kinases-2 (CDK2) are members of the serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicates that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, we collected one-hundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket submitting to short MD simulations (10ns) and free energy calculation by means of MM-GBSA. The calculate ∆G values have been compared with …

VHTS CDK2 INHIBITORS MOLECULAR DYNAMICS PHARMACOPHORE MODELLING DOCKING
researchProduct

CHA on CDK2: a way to identify the best pharmacophore model for the virtual screening of new inhibitors

2018

Cyclin-dependent kinase-2 (CDK2) is a member of serine/threonine protein kinases family. It plays an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidences indicate that excessive expression of CDK2 should cause abnormal cell cycle regulation. Therefore, CDK2 has been considered a potential therapeutic target for cancer therapy. In this work, we used a modelling approach that incorporates flexibility based on extensive MD simulations of protein−ligand complexes into structure-based pharmacophore modeling and virtual screening to identify new CDK2 inhibitors. One-hundred and forty-nine CDK2-inhibit…

cdk2 pharmacophore modelling virtual screening
researchProduct

Sulfonamide moiety as "molecular chimera" in the design of new drugs.

2021

Background: The -SO2NH- group is of great significance in modern pharmaceutical use since, in sulfa-drugs, it is possible to introduce easily chemical modifications, and even small changes may lead to an improved version of an already existing drug. Objective: This paper aims to describe updated information in the sulfonamide field with a particular focus on new mechanisms of action, especially if discovered by employing computational approaches. Methods: Research articles that focused on the use of the sulfonamide moiety for the design, synthesis, and in vitro/in vivo tests of various diseases were collected from various search engines like PubMed, Science Direct, Google Scholar, and Scop…

sulfonamide moietyPharmacologyOrganic Chemistrymolecular chimeraSettore CHIM/08 - Chimica FarmaceuticaBiochemistrymolecular dynamicsin silico drug designdockingDrug Discoverypharmacophore modelingMolecular Medicinealkylsulfonamidesaryl/heteroarylsulfonamidesCurrent medicinal chemistry
researchProduct